Last reviewed · How we verify
Quadratus triamcinolone
Triamcinolone is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Triamcinolone is a synthetic corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and allergic skin conditions, Rheumatoid arthritis and other inflammatory joint diseases, Asthma and allergic respiratory conditions.
At a glance
| Generic name | Quadratus triamcinolone |
|---|---|
| Also known as | Quadratus lumborum infiltration with triamcinolone. |
| Sponsor | Hospital de Braga |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Dermatology / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Triamcinolone exerts its anti-inflammatory effects through glucocorticoid receptor activation, which leads to decreased production of inflammatory mediators such as cytokines, chemokines, and adhesion molecules. This results in reduced immune cell infiltration and suppression of both humoral and cell-mediated immune responses. The drug is commonly used in topical, intralesional, or systemic formulations depending on the therapeutic indication.
Approved indications
- Inflammatory and allergic skin conditions
- Rheumatoid arthritis and other inflammatory joint diseases
- Asthma and allergic respiratory conditions
- Autoimmune and inflammatory disorders
Common side effects
- Skin atrophy (with topical use)
- Hypothalamic-pituitary-adrenal (HPA) axis suppression
- Immunosuppression and increased infection risk
- Hyperglycemia
- Osteoporosis (with chronic systemic use)
- Mood changes and insomnia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quadratus triamcinolone CI brief — competitive landscape report
- Quadratus triamcinolone updates RSS · CI watch RSS
- Hospital de Braga portfolio CI